PharmAla Introduces New Prescriber’s Portal for MDMA Therapy

pharmala biotech

Launch of the Prescriber’s Portal

PharmAla Biotech Holdings Inc., a biotechnology company specializing in the development and manufacturing of LaNeo™ MDMA and its derivatives, announced the launch of its Prescribers Portal. This online resource, accessible exclusively to pre-approved medical professionals, aims to educate them about MDMA and its clinical uses. The portal is now live and can be accessed at their official website.

Educational and Regulatory Updates

With the anticipated review of MDMA for treating PTSD by the US Food and Drug Administration and increased insurance coverage in Canada for psychedelic-based treatments, PharmAla recognizes the need for high-quality educational resources. Nicholas Kadysh, CEO of PharmAla, emphasized the portal’s role in keeping medical practitioners informed about the latest research and regulatory changes concerning MDMA, especially for treating Post-Traumatic Stress Disorder.

Tools and Resources for Medical Practitioners

PharmAla’s portal offers various tools and resources to aid medical practitioners in treating patients. The company is also developing an accredited training and Continuing Education module for physicians in Canada and Australia, focusing on MDMA’s clinical applications.

To register for access to the portal, you can visit their website at https://sap.pharmala.ca/physician-portal-application/